Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma Newswire.ca - Wed Feb 7, 5:47AM CST

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

BGNE : 136.82 (-1.14%)
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib) Newswire.ca - Wed Jan 31, 5:47AM CST

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

BGNE : 136.82 (-1.14%)
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond Motley Fool - Mon Jan 15, 5:30AM CST

These five biotech companies could have a lot of room to run.

AMGN : 264.99 (-0.20%)
ARGX : 371.27 (-1.33%)
BGNE : 136.82 (-1.14%)
CRSP : 58.27 (-0.77%)
IMVT : 30.55 (+0.26%)
Author
7 Best Cancer Stocks to Invest in Now MarketBeat - Fri Jul 28, 2023

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

EXEL : 22.82 (+0.53%)
GILD : 67.66 (-0.13%)
NVS : 93.22 (-1.26%)
ON : 64.62 (-1.55%)
PFE : 25.84 (-0.27%)
MDCO : 84.90 (-0.07%)
MRK : 125.70 (-0.39%)
KURA : 18.78 (-1.21%)
AZN.LN : 10,902.000 (-1.11%)
BGNE : 136.82 (-1.14%)
Author
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus MarketBeat - Thu Jul 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 67.66 (-0.13%)
AMGN : 264.99 (-0.20%)
BMY : 48.41 (-0.21%)
NVS : 93.22 (-1.26%)
BGNE : 136.82 (-1.14%)
JSPR : 25.35 (-3.61%)
VIGL : 3.20 (+1.27%)
ALVR : 0.7401 (-0.80%)
RCUS : 16.47 (+1.10%)
FLACU : 9.50 (+2.48%)
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE PR Newswire - Fri Jun 30, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BGNE : 136.82 (-1.14%)
BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE PR Newswire - Fri Jun 23, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BGNE : 136.82 (-1.14%)
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults Newswire.ca - Tue May 30, 2023

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's...

BGNE : 136.82 (-1.14%)
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China Business Wire - Sat May 6, 2023

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib),...

BGNE : 136.82 (-1.14%)
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments Business Wire - Thu May 4, 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones....

BGNE : 136.82 (-1.14%)

Barchart Exclusives

2 'Strong Buy' Dividend Stocks That Have Raised Their Payouts in 2024 Barchart - 1 hour ago
Costco and TJX Companies are top dividend stock picks for 2024, with both companies increasing their shareholder payouts despite increasing market volatility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot